Raymond James upgraded Immunovant to Outperform from Market Perform with a $40 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMVT:
- Immunovant Announces Proposed Offering of $300 Million of Common Stock
- Immunovant (NASDAQ: IMVT) Surges after Remarkable Drug Results
- OmniAb should be up after IMVT-1402 data, says Truist
- Immunovant data ‘further establishes’ 1402 competitive profile, says BofA
- Immunovant jumps 51% to $30.68 after Phase 1 IMVT-1402 results